| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Nadia Birocco | |
| Libero Ciuffreda | |||
| Isabella Chiappino | |||
| Maria Antonietta Satolli | |||
| Rosella Spadi | |||
| Agostino Ponzetti | |||
| Federica Brusa | |||
| P2860 | cites work | 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy | Q44177883 |
| Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer | Q44650366 | ||
| FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. | Q44677340 | ||
| Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer | Q45106840 | ||
| Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer | Q46133123 | ||
| Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer | Q46199274 | ||
| Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer | Q46448479 | ||
| Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy | Q46537704 | ||
| Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of | Q46604466 | ||
| Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial | Q46748088 | ||
| Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma | Q48113129 | ||
| Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. | Q52875756 | ||
| Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarcinoma. | Q53379409 | ||
| Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. | Q53507125 | ||
| Pancreatic Adenocarcinoma | Q55880513 | ||
| Can We Prevent Pancreatic Disease? | Q56779133 | ||
| FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study | Q57758065 | ||
| Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies | Q57758319 | ||
| Microwave Ablation of Pancreatic Head Cancer: Safety and Efficacy | Q57998653 | ||
| Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group | Q69919858 | ||
| Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis | Q84100587 | ||
| 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma | Q84583196 | ||
| Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability | Q85646726 | ||
| Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma | Q86226098 | ||
| Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages | Q21092323 | ||
| Cancer genome landscapes | Q22242276 | ||
| Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer | Q24245085 | ||
| Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | Q24595981 | ||
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
| FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience | Q24622390 | ||
| A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas | Q27853017 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| New challenges in perioperative management of pancreatic cancer | Q28082422 | ||
| Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer | Q29547558 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Pancreatic cancer | Q29616288 | ||
| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | Q29616728 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| High intensity focused ultrasound: a noninvasive therapy for locally advanced pancreatic cancer | Q30423784 | ||
| Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer | Q30434098 | ||
| Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer | Q30452636 | ||
| Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study | Q33349410 | ||
| Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer | Q33360410 | ||
| A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer | Q33367733 | ||
| A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. | Q41743831 | ||
| Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer | Q43586373 | ||
| Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study | Q43679835 | ||
| Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? | Q43960823 | ||
| Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma | Q33371777 | ||
| The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis | Q33374920 | ||
| Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group | Q33385281 | ||
| A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). | Q33395577 | ||
| Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotini | Q33416585 | ||
| Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies | Q33632628 | ||
| FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study | Q33823212 | ||
| Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer | Q34008107 | ||
| Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 | Q34049250 | ||
| Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). | Q34049260 | ||
| Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). | Q34080597 | ||
| Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium | Q34094983 | ||
| Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival | Q34310131 | ||
| Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer | Q34314018 | ||
| Effect of initiating a multidisciplinary care clinic on access and time to treatment in patients with pancreatic adenocarcinoma | Q34335066 | ||
| Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials | Q34345296 | ||
| Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer | Q34357427 | ||
| S-1 in the treatment of pancreatic cancer | Q34467156 | ||
| Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate | Q34550827 | ||
| Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. | Q34557866 | ||
| Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer | Q34596369 | ||
| Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer | Q34613161 | ||
| Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study | Q34617300 | ||
| Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group | Q34629100 | ||
| A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma | Q34631279 | ||
| Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial | Q34646032 | ||
| Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? | Q34659974 | ||
| Helicobacter pylori and pancreatic diseases | Q34666355 | ||
| Risk factors for pancreatic cancer: a summary review of meta-analytical studies | Q34667061 | ||
| Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review | Q34677746 | ||
| Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. | Q35102975 | ||
| Systematic review of novel ablative methods in locally advanced pancreatic cancer. | Q35113615 | ||
| Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies | Q35136815 | ||
| Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer | Q35147520 | ||
| Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma | Q35202400 | ||
| Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer | Q35659511 | ||
| The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience | Q35695811 | ||
| Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer | Q35832274 | ||
| A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. | Q35901707 | ||
| Whole genomes redefine the mutational landscape of pancreatic cancer | Q35911034 | ||
| Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer | Q35944817 | ||
| Expanding surgical treatment of pancreatic cancer: the role of regional chemotherapy | Q36033068 | ||
| FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts | Q36214563 | ||
| Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial | Q36476666 | ||
| Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer | Q36550798 | ||
| A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer | Q36612255 | ||
| Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas | Q36646900 | ||
| Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results | Q36764997 | ||
| Allergies and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium | Q37127919 | ||
| Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. | Q37252144 | ||
| A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer | Q37424087 | ||
| Inflammation and pancreatic cancer: an evidence-based review | Q37546454 | ||
| Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies | Q37617957 | ||
| Focal cystic pancreatic lesions: assessing variation in radiologists' management recommendations | Q37835584 | ||
| Insulin resistance and cancer: epidemiological evidence | Q38031219 | ||
| Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis | Q38052795 | ||
| Alleviating visceral cancer pain in patients with pancreatic cancer using cryoablation and celiac plexus block | Q38069860 | ||
| Biology and clinical applications of pancreatic cancer stem cells | Q38102108 | ||
| Stereotactic body radiotherapy in the treatment of pancreatic cancer | Q38196488 | ||
| Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer | Q38294104 | ||
| The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings | Q38366159 | ||
| Stage III pancreatic cancer and the role of irreversible electroporation | Q38383285 | ||
| Pancreatic cancer: from state-of-the-art treatments to promising novel therapies | Q38396634 | ||
| Cystic tumors of the pancreas: Opportunities and risks | Q39006342 | ||
| Radiotherapy and radioembolization for liver metastases | Q39191482 | ||
| Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites | Q39455528 | ||
| A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer | Q40297178 | ||
| Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study | Q41021002 | ||
| Italian cancer figures, report 2014: Prevalence and cure of cancer in Italy | Q41249095 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 27-43 | |
| P577 | publication date | 2016-02-10 | |
| P1433 | published in | World journal of clinical oncology | Q27723540 |
| P1476 | title | Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians | |
| P478 | volume | 7 |
| Q38662058 | A Comparative Study of Clinical Intervention and Interventional Photothermal Therapy for Pancreatic Cancer |
| Q54977394 | A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. |
| Q45559181 | Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. |
| Q33687038 | Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. |
| Q64070346 | Development and validation of a nomogram to predict liver metastasis in patients with pancreatic ductal adenocarcinoma: a large cohort study |
| Q90701969 | Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer |
| Q58706536 | Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells |
| Q97424482 | Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer |
| Q38731184 | Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials. |
| Q37641809 | Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. |
| Q64252172 | Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer |
| Q89701894 | Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells |
| Q30396675 | Leptin-Notch signaling axis is involved in pancreatic cancer progression |
| Q90697648 | Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine |
| Q89962447 | Long noncoding RNA LINC00657 enhances the malignancy of pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on microRNA-433 to increase PAK4 expression |
| Q53700817 | Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10. |
| Q60931541 | Restoration of miRNA-148a in pancreatic cancer reduces invasion and metastasis by inhibiting the Wnt/β-catenin signaling pathway via downregulating maternally expressed gene-3 |
| Q64901574 | Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. |
| Q33868592 | Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study |
| Q48253065 | Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. |
| Q55098659 | The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine. |
| Q49457016 | The application of a three-dimensional visualized seed planning and navigation system in 125I seed implantation for pancreatic cancer |
| Q37677535 | The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future? |
| Q60609561 | Therapeutic developments in pancreatic cancer: current and future perspectives |
| Q90711491 | Vitamin D receptor activation and photodynamic priming enable durable low-dose chemotherapy |
| Q54959414 | miR-128 induces pancreas cancer cell apoptosis by targeting MDM4. |
Search more.